Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study

Alzheimer's and Dementia

Volumn 10, Issue 3, 2014, Pages 366-371

  Peterson, David ^a   Munger, Caitlin ^a   Crowley, Jared ^a   Corcoran, Chris ^b   Cruchaga, Carlos ^c   Goate, Alison M ^c   Norton, Maria C ^b   Green, Robert C ^d   Munger, Ronald G ^b   Breitner, John C S ^e   Welsh Bohmer, Kathleen A ^f   Lyketsos, Constantine ^g   Tschanz, Joann ^b   Kauwe, John S K ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Association; Genetics; MAPT; PPP3R1; Rate of progression

Indexed keywords

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DEMENTIA RATING; DISEASE COURSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAPT GENE; PPP3R1 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; BIOLOGICAL MODEL; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; HETEROZYGOTE; PATHOPHYSIOLOGY; RISK; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME;

CALCINEURIN; MAPT PROTEIN, HUMAN; PPP3R1 PROTEIN, HUMAN; TAU PROTEIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CALCINEURIN; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HETEROZYGOTE; HUMANS; LINEAR MODELS; MALE; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TIME FACTORS;

EID: 84899645164     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.02.010     Document Type: Article

References (26)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
2. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009; 84:35-43.
3. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008;83:623-32.
4. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009;41:192-8.
5. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-8.
6. Feulner TM, Laws SM, Friedrich P,Wagenpfeil S,Wurst SH, Riehle C, et al. Examination of the current top candidate genes for AD in a genome- wide association study. Mol Psychiatry 2010;15:756-66.
7. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-93.
8. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/ MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-35.
9. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010;67:1473-84.
10. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9.
11. Li H,Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008;65:45-53.
12. Naj AC, Jun G, BeechamGW,Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43:436-41.
13. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;;303:1832-40.
14. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A 2008;105:8050-4.
15. Cruchaga C, Kauwe JSK, Mayo K, Spiegel N, Bertelsen S, Nowotny P, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 2010; 6:e1001101.
16. Breitner JC,Wyse BW, Anthony JC,Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999;53:321-31.
17. Tschanz JT,Welsh-Bohmer KA, Plassman BL, Norton MC,WyseBW, Breitner JC. An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the cache county study. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15:28-38.
18. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-22.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
20. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, et al. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 2011;19:532-42.
21. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009;66:638-45.
22. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201-9.
23. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15:869-77. xi-xii.
24. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008; 29:1466-73.
25. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012;78:709-19.
26. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012;7:e30525.